Targeting the Extracellular Matrix: Overcoming Biological Barriers to Unlock Novel Therapeutic Opportunities

• Analyzing why components of the extracellular matrix (ECM) could be ideal targets for radioligand therapy
• Exploring challenges associated with delivering therapeutic doses when targeting components of the ECM
• Reviewing early development strategy for a novel fibrin targeted radioligand therapy

New Company for 2026

Speakers:

Cara Ferreira

Chief Executive Officer

Lumina Pharm